Major advances have been made in precision medicine of breast cancer patients with a
series of molecular targeted therapies now in clinical use or in late clinical development …

In recent decades, there has been a significant amount of research into breast cancer, with
some important breakthroughs in the treatment of both primary and metastatic breast …

Breast cancer is the most prevalent non-skin cancer diagnosed in females and developing
novel therapeutic strategies to improve patient outcomes is crucial. The immune system …

Background Preclinical evidence from us and others demonstrates that the anticancer
effects of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors can be enhanced with focal …

Abstract Anti-CDK4/6 therapy has been employed for the treatment for head and neck
squamous cell carcinoma (HNSCC) with CDK4/6 hyperactivation, but the response rate is …

Radiation therapy is an important component of cancer treatment scheduled for cancer
patients, although it can cause numerous deleterious effects. The use of adjuvant molecules …

Purpose Radiation therapy (RT) and hormone receptor (HR) inhibition are used for the
treatment of HR-positive breast cancers; however, little is known about the interaction of the …

Background: Centrosomal Protein 55 (CEP55) was initially described as a main participant
in the final stage of cytokinesis. Further research identified CEP55 as a cancer-testis antigen …

Abstract Introduction: miR-132-3p acts in normal breast development and its downregulation
has been documented in breast cancer. One of the targets of miR-132-3p is RB1 which is …

CDK4/6 inhibitors are nowadays commonly used in metastatic HR+/HER2− breast cancer.
Herein, we report a literature review regarding the benefits and risks of their combination …